Sci Tranl Med:新发现有助治疗鳞状细胞癌

2018-07-01 陈善辉 新华网

澳大利亚一项新研究说,对于皮肤和口腔鳞状细胞癌,如果能将一种蛋白质留在癌细胞中,有助防止癌细胞出现抗药性。

澳大利亚一项新研究说,对于皮肤和口腔鳞状细胞癌,如果能将一种蛋白质留在癌细胞中,有助防止癌细胞出现抗药性。

鳞状细胞癌多见于有鳞状上皮覆盖的部位,如皮肤、口腔和食管等。

澳大利亚昆士兰大学日前宣布,该校研究人员发现在皮肤和口腔鳞状细胞癌中,一种名为E2F7的蛋白质对于细胞的抗药性有重要影响。在正常细胞里,这种蛋白质停留在细胞核内并能防止细胞出现抗药性;而在癌变细胞中,这种蛋白质脱离了细胞核,导致细胞对药物不再敏感。

昆士兰大学副教授尼古拉斯·桑德斯说,他们发现一种新药物,能让E2F7留在细胞核中,从而使癌细胞对化疗药物敏感,提高治疗鳞状细胞癌的疗效。

相关论文已经发表在新一期美国《科学·转化医学》杂志上。

原始出处:

Natalia Saenz-Ponce, Rachael Pillay, Lilia Merida de Long, et.al. Targeting the XPO1-dependent nuclear export of E2F7 reverses anthracycline resistance in head and neck squamous cell carcinomas. Science Translational Medicine  27 Jun 2018

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1978709, encodeId=1c6919e870968, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sat Jul 14 00:47:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657033, encodeId=847b165e03333, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Thu Dec 06 07:47:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921226, encodeId=89f71921226e3, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Sat Jun 08 04:47:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608914, encodeId=701e160891462, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jul 03 08:47:00 CST 2018, time=2018-07-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1978709, encodeId=1c6919e870968, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sat Jul 14 00:47:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657033, encodeId=847b165e03333, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Thu Dec 06 07:47:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921226, encodeId=89f71921226e3, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Sat Jun 08 04:47:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608914, encodeId=701e160891462, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jul 03 08:47:00 CST 2018, time=2018-07-03, status=1, ipAttribution=)]
    2018-12-06 bsmagic9140
  3. [GetPortalCommentsPageByObjectIdResponse(id=1978709, encodeId=1c6919e870968, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sat Jul 14 00:47:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657033, encodeId=847b165e03333, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Thu Dec 06 07:47:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921226, encodeId=89f71921226e3, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Sat Jun 08 04:47:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608914, encodeId=701e160891462, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jul 03 08:47:00 CST 2018, time=2018-07-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1978709, encodeId=1c6919e870968, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sat Jul 14 00:47:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657033, encodeId=847b165e03333, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Thu Dec 06 07:47:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921226, encodeId=89f71921226e3, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Sat Jun 08 04:47:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608914, encodeId=701e160891462, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jul 03 08:47:00 CST 2018, time=2018-07-03, status=1, ipAttribution=)]

相关资讯

JAMA Dermat:第8版vs第7版:AJCC癌症分期手册头颈部皮肤鳞状细胞癌肿瘤分类有何变化?

刚刚发布的第八版AJCC癌症分期手册与第七版相比,在头颈部皮肤鳞状细胞癌上有哪些区别?能否保证其独特性、一致性和单一性?日前,美国波士顿布列根和妇女医院皮肤科的Chrysalyne D. Schmults博士对第七版和第八版头颈部皮肤鳞状细胞癌分类进行了比较,并将结果发表于12月20日的《JAMA Dermatology》上。

《2018 NCCN外阴鳞癌临床实践指南(第一版)》解读

2017 年10 月27 日,NCCN 更新发布了《2018NCCN外阴鳞癌临床实践指南(第一版)》(简称“指南”),现对该指南进行简要解读。

Int Oral Max Surg:FMISO-PET评价低氧体积作为口腔鳞状细胞癌预后的因素之一

18F-氟米松硝苯胺正电子发射断层扫描(FMISO-PET)可检测肿瘤缺氧。很少有研究评估新的PET参数(包括缺氧量(HV),代谢肿瘤体积(MTV)和总病灶糖酵解(TLG))与手术治疗的口腔鳞状细胞癌(OSCC)患者的5年生存率之间的关系。

PLos One:组织学亚型与肺癌中的肌肉减少症无关

这项研究发现肌肉减少症与LCA中的老年、男性、晚期、合并症和低BMI显著相关。然而,组织学亚型并不是肌肉减少症存在的独立因素。

肾鳞状细胞癌1例

患者女性,70岁。右侧腰背部胀痛不适半月余,伴尿频、尿急及排尿踌躇费力。

Ann Oncol:顺铂+西妥昔单抗+再放疗对于复发性或第二原发性头颈部鳞状细胞癌患者可行

头颈部鳞状细胞癌患者外照射治疗后,常会发生局部区域复发,造成死亡。对于复发性或第二原发性头颈部鳞状细胞癌患者,哪种治疗方案有效性强,且安全性高?美国克里夫兰大学医院凯斯西储大学放射肿瘤系Min Yao博士给出了一个可行的方案。1月15日,《Annals of Oncology》对其研究结果进行了报道。背景和目的:外照射疗法(XRT)对于头颈部鳞状细胞癌(HNSCC)的治疗来说仍然是必要的。XR